Abstract
Background: The IBD Qorus Collaborative aims to reduce variation and increase the value of care for the adult inflammatory bowel disease (IBD)
community. To evaluate the success of the collaborative, we aimed to develop a balanced set of outcome measures that reflect a multistakeholder
view of value in IBD care. To achieve this, we used the Clinical Value Compass framework and engaged a mixed-stakeholder group to conduct a
modified Delphi process. The end result was a 10-measure set to assess the value of IBD care.
Method: The modified Delphi process included 3 iterative rounds of blinded voting and interactive webinar-style discussion. We recruited 18 participants for the Delphi panel, including clinicians, researchers, patients, Crohn’s & Colitis Foundation staff, and payers. Participants first identified
constructs to measure, then identified the tools to measure those constructs. A literature review and environmental scan of current measures
in 4 domains were performed, and relevant measures were proposed for discussion and voting in each domain. Throughout the process, participants were invited to contribute additional measures.
Conclusion: The modified Delphi process led to selection of 10 value measures across 4 domains: (1) patient experience; (2) functional status;
(3) clinical status; and (4) health care costs and utilization. We have successfully completed a 3-stage modified Delphi process to develop a
balanced set of value measures for adult IBD care. The value measure set expands upon prior efforts that have established quality measures
for IBD care by adding cost and experience of care elements. This work positions IBD Qorus to better assess, study, improve, and demonstrate
value at individual, system, and population levels and will inform and empower related research, improvement, and implementation efforts.
community. To evaluate the success of the collaborative, we aimed to develop a balanced set of outcome measures that reflect a multistakeholder
view of value in IBD care. To achieve this, we used the Clinical Value Compass framework and engaged a mixed-stakeholder group to conduct a
modified Delphi process. The end result was a 10-measure set to assess the value of IBD care.
Method: The modified Delphi process included 3 iterative rounds of blinded voting and interactive webinar-style discussion. We recruited 18 participants for the Delphi panel, including clinicians, researchers, patients, Crohn’s & Colitis Foundation staff, and payers. Participants first identified
constructs to measure, then identified the tools to measure those constructs. A literature review and environmental scan of current measures
in 4 domains were performed, and relevant measures were proposed for discussion and voting in each domain. Throughout the process, participants were invited to contribute additional measures.
Conclusion: The modified Delphi process led to selection of 10 value measures across 4 domains: (1) patient experience; (2) functional status;
(3) clinical status; and (4) health care costs and utilization. We have successfully completed a 3-stage modified Delphi process to develop a
balanced set of value measures for adult IBD care. The value measure set expands upon prior efforts that have established quality measures
for IBD care by adding cost and experience of care elements. This work positions IBD Qorus to better assess, study, improve, and demonstrate
value at individual, system, and population levels and will inform and empower related research, improvement, and implementation efforts.
| Original language | English |
|---|---|
| Pages (from-to) | 327-336 |
| Number of pages | 10 |
| Journal | Inflammatory Bowel Diseases |
| Volume | 28 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 25 May 2021 |
| Externally published | Yes |
Bibliographical note
Acknowledgments:The authors acknowledge the significant contributions of the
IBD Qorus Value Measurement Delphi Panel for lending their
time and expertise to these recommendations. The authors
also acknowledge the ongoing contributions of our patient
partners, without whom this work would not be possible.
IBD Qorus is made possible in part by the support of AbbVie,
AMAG Pharmaceuticals, Eli Lilly, Helmsley Charitable
Trust, Janssen Biotech, Inc., Luitpold Pharmaceuticals, Inc.,
Nephroceuticals LLC, Nestle Health Sciences, Pfizer, Inc.,
Takeda Pharmaceuticals U.S.A., Inc., and UCB.
Fingerprint
Dive into the research topics of 'Development of Balanced Whole System Value Measures for Inflammatory Bowel Disease Care in the IBD Qorus Collaborative Using a Modified Delphi Process'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver